Polynucleotides
PN and PDRN: why the terms are not interchangeable
PN and PDRN are both DNA-derived materials, but the labels do not describe identical products. Understanding the difference helps patients ask better questions about formulation, evidence and suitability.
Similar names do not mean the same material
Polynucleotide (PN) and polydeoxyribonucleotide (PDRN) are terms used for DNA-derived chains, but they should not automatically be treated as synonyms. Published reviews describe differences in chain size, molecular weight, physical properties and proposed biological activity. The terminology has nevertheless been used inconsistently in research and marketing.
That uncertainty matters because a patient is not receiving an abstract ingredient: they are receiving a specific finished product, prepared at a particular concentration and injected in a particular way. A claim made for one formulation cannot simply be transferred to every product carrying PN, PDRN or ‘salmon DNA’ wording.
Why molecular size and formulation matter
PN is generally described as containing longer, higher-molecular-weight chains, while PDRN is usually discussed as shorter fragments with different proposed signalling effects. A 2025 review compared these characteristics, but this remains a developing field and there is no universally adopted naming system across all publications and commercial products.
Other ingredients also matter. Products may differ in concentration, viscosity, source material, purification, added hyaluronic acid or local anaesthetic, syringe volume and intended treatment area. These features can affect handling, injection technique, comfort and the immediate skin response. The highest number on a label is not automatically the best choice.
Injectable evidence does not apply to a serum
A topical cosmetic, microneedling solution and injectable medical device do not place material in the same tissue layer. Even if their ingredient lists use similar language, their absorption, permitted use, evidence and risks are different. Results from an injectable study should not be used to promise that a cream or serum will behave in the same way.
Likewise, combining a product with microneedling or another procedure creates a different treatment from injection alone. It requires its own assessment, infection-control plan and supporting product instructions. Social-media terms such as ‘salmon sperm facial’ can blur these distinctions and are not a substitute for the exact product name and intended use.
What the clinical evidence can tell us
A 2025 systematic review of aesthetic PN treatment found nine studies involving 219 patients. It reported encouraging findings for wrinkles, texture and elasticity, but rated the evidence as low or moderate quality and identified variation in treatment areas and techniques. This limits confident comparisons between products and protocols.
A newer systematic review of randomised trials also cautioned against treating PN and PDRN as one therapeutic category despite possible biological differences. Laboratory mechanisms and animal research may help form hypotheses, but they do not by themselves prove a visible cosmetic benefit, its size or how long it will last in an individual patient.
Downtime and adverse effects still apply
Whichever term appears on the label, an injectable procedure can cause temporary redness, tenderness, swelling, bruising, itching and raised injection points. Less common problems may include infection, inflammation, persistent lumps or an allergic reaction. The area, formulation, injection depth and individual health can influence both downtime and risk.
Contact the clinic promptly about severe or increasing pain, spreading redness or heat, discharge, fever, marked swelling, unusual skin colour or another worsening symptom. Sudden visual disturbance, breathing difficulty or features of a severe allergic reaction require urgent medical help rather than waiting for a routine review.
Questions to ask at consultation
Ask for the exact product name, whether it is PN or PDRN, its intended treatment area, the proposed course and which evidence supports that plan. The practitioner should also explain alternatives, realistic limitations, aftercare and how a complication would be managed. Vague ingredient terminology should not replace informed consent.
Active infection or inflammation may mean postponing treatment. Pregnancy or breastfeeding, allergies—including relevant source-material allergies—autoimmune or other medical conditions, medicines affecting bleeding and previous injectable reactions need individual discussion. Safe selection depends on the person and the specific product, not on a fashionable ingredient name alone.